ClinicalTrials.gg
CompletedNCT02685033Updated Jan 4, 2019Results posted

Study on the Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Participants With Osteomyelitis

A Phase 2 interventional study of Dalbavancin and Comparator in Osteomyelitis, sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc. Completed at 1 site in Ukraine. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-04.

Sponsored by Durata Therapeutics Inc., an affiliate of Allergan plc (part of AbbVie) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This clinical study will be a single-center, randomized, open-label, active-controlled, parallel-group study comparing dalbavancin to standard of care (SOC) therapy in osteomyelitis.

02

Conditions studied

  • Osteomyelitis

Browse trials for

Keywords

  • Osteomyelitis
  • dalbavancin
  • antibiotic
03

In context

Osteomyelitis

105 studies on the registry are indexed under Osteomyelitis; 30 are open to participants now.

This study's enrollment of 80 is close to the median of 74 across 60 interventional studies indexed under Osteomyelitis.

Browse Osteomyelitis studies →

Lead sponsor

Durata Therapeutics Inc., an affiliate of Allergan plc is the lead sponsor of 6 studies on the registry; none are open to participants now.

First submitted before Durata Therapeutics Inc. became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of osteomyelitis (first episode) defined by:
  • Pain or point tenderness upon palpation or probing to bone
  • Plain radiograph or Magnetic resonance imaging (MRI) consistent with osteomyelitis (indistinctly marginated edema-like pattern of bone marrow hypointensity on unenhanced T1-weighted sequences, hyperintensity on fat-saturated T2-weighted and Short tau inversion recovery (STIR) sequences and/or abnormal enhancement on gadolinium-enhanced fat-saturated T2-weighted sequences, with or without visible periostitis or cortical bone destruction) OR Gram-positive cocci documented on a baseline Gram-stain from a bone specimen
  • Elevated C-reactive protein (CRP) (low sensitivity) above the (ULN) (reference range for low sensitivity CRP is 3-10 mg/L)
  • Participants must be willing and able, if discharged from the hospital, to return to the hospital or a designated clinic for scheduled visits, treatment, laboratory tests, and other outpatient procedures as required by the protocol.

Exclusion criteria

Exclusion Criteria:

  • Treatment with an drug within 30 days preceding the first dose of investigational product.
  • Receipt of > 24 hours of potentially effective IV antibacterial therapy for osteomyelitis within 96 hours of randomization, unless the pathogen isolated was documented to be Methicillin-resistant Staphylococcus aureus (MRSA) that was resistant to the administered antibiotic.
  • A prior episode of osteomyelitis, or a failed course of therapy for osteomyelitis.
  • Infection associated with a burn wound, with a sacral decubitus ulcer, or with multiple sites of osteomyelitis.
  • Septic arthritis that is non-contiguous to osteomyelitis, as diagnosed by isolation of a pathogen from synovial fluid culture.
  • /immune deficiency
  • Evidence of Gram-negative bacteria by Gram stain in the absence of Gram-positive organisms.
  • Gram-negative bacteremia
  • Patients with concomitant endocarditis, necrotizing fasciitis, or prosthetic material at the site of infection at the time of study initiation.
  • Infection due to an organism known prior to study entry to not be susceptible to dalbavancin (dalbavancin mean inhibitory concentration [MIC] > 0.12 μg/mL) or vancomycin (vancomycin MIC > 2 μg/mL).
  • Concomitant systemic antibacterial therapy for Gram-positive infections (eg, rifampin, gentamicin).
  • Known or suspected to glycopeptide antibiotics.
  • Patients with a rapidly fatal illness, who are not expected to survive for 3 months.
  • Pregnant or nursing females; positive urine (or serum) pregnancy test at Screening (pre-menopausal females only) or after admission (prior to dosing)
  • Sexually active females of who are unwilling or unable to use an acceptable method of from at least the first dose of study drug until the last pregnancy test.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (actual)

Study arms

  • Experimental
    Dalbavancin

    Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1 and Day 8. If creatinine clearance was \< 30 milliliters per minute (mL/min) and participant was not receiving regular hemodialysis or peritoneal dialysis, dalbavancin dose was decreased to 1000 mg.

    Drug: Dalbavancin

  • Active comparator
    Standard of Care

    Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks.

    Drug: Comparator

Interventions

  • Also known as: Dalvance®, Xydalba™

  • DrugComparator
06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population

    Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

    Time frame: Day 42

  2. Percentage of Participants With Clinical Response at Day 365 in the CE Population

    Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

    Time frame: Day 365

Secondary outcomes

  1. Percentage of Participants With Clinical Improvement at Day 21 in the mITT Population

    Clinical improvement was defined as no worsening of pain from baseline, if present (subjective pain and/or point tenderness), and improvement in inflammation (as measured by C-reactive protein \[CRP\]).

    Time frame: Baseline to Day 21

  2. Percentage of Participants With Clinical Improvement at Day 21 in the CE Population

    Clinical improvement was defined as no worsening of pain from baseline, if present (subjective pain and/or point tenderness), and improvement in inflammation (as measured by C-reactive protein \[CRP\]).

    Time frame: Baseline to Day 21

  3. Percentage of Participants With Clinical Response at Day 42 in the mITT Population

    Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

    Time frame: Day 42

  4. Percentage of Participants With Clinical Response at Day 42 in the Microbiological Modified Intent-to-Treat (Micro-mITT) Population

    Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

    Time frame: Day 42

  5. Percentage of Participant With Clinical Response at Day 180 in the mITT Population

    Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

    Time frame: Day 180

  6. Percentage of Participants With Clinical Response at Day 180 in the CE Population

    Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

    Time frame: Day 180

  7. Percentage of Participants With Clinical Response at Day 365 in the mITT Population

    Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

    Time frame: Day 365

  8. Number of Participants With Clinical Cure by Baseline Pathogen at Day 42 in the CE Population

    Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

    Time frame: Day 42

  9. Number of Participants With Clinical Cure by Baseline Pathogen at Day 180 in the CE Population

    Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

    Time frame: Day 180

07

Results

Posted Jan 4, 2019

Participant flow

Participant flow — Overall Study
MilestoneDalbavancinStandard of Care
Started7010
Completed678
Not completed32
Withdrew: Withdrawal of consent01
Withdrew: Lost to follow-up21
Withdrew: Adverse event10

Outcome measures

PrimaryPercentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

Time frame:
Day 42
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Day 42 in the Clinically Evaluable (CE) Population
percentage of participantsDalbavancinStandard of Care
Clinical Cure97.0 (89.6 to 99.6)87.5 (47.3 to 99.7)
Clinical Failure0.0 (NA to NA)12.5 (NA to NA)
Indeterminate3.0 (NA to NA)0.0 (NA to NA)
SecondaryPercentage of Participants With Clinical Improvement at Day 21 in the mITT Population

Clinical improvement was defined as no worsening of pain from baseline, if present (subjective pain and/or point tenderness), and improvement in inflammation (as measured by C-reactive protein \[CRP\]).

Time frame:
Baseline to Day 21
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Improvement at Day 21 in the mITT Population
percentage of participantsDalbavancinStandard of Care
Percentage of Participants With Clinical Improvement at Day 21 in the mITT Population94.0 (85.4 to 98.3)62.5 (24.5 to 91.5)
SecondaryPercentage of Participants With Clinical Improvement at Day 21 in the CE Population

Clinical improvement was defined as no worsening of pain from baseline, if present (subjective pain and/or point tenderness), and improvement in inflammation (as measured by C-reactive protein \[CRP\]).

Time frame:
Baseline to Day 21
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Improvement at Day 21 in the CE Population
percentage of participantsDalbavancinStandard of Care
Percentage of Participants With Clinical Improvement at Day 21 in the CE Population94.0 (85.4 to 98.3)62.5 (24.5 to 91.5)
SecondaryPercentage of Participants With Clinical Response at Day 42 in the mITT Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

Time frame:
Day 42
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Day 42 in the mITT Population
percentage of participantsDalbavancinStandard of Care
Clinical Cure97.0 (89.6 to 99.6)87.5 (47.3 to 99.7)
Clinical Failure0.0 (NA to NA)12.5 (NA to NA)
Indeterminate3.0 (NA to NA)0.0 (NA to NA)
SecondaryPercentage of Participants With Clinical Response at Day 42 in the Microbiological Modified Intent-to-Treat (Micro-mITT) Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

Time frame:
Day 42
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Day 42 in the Microbiological Modified Intent-to-Treat (Micro-mITT) Population
percentage of participantsDalbavancinStandard of Care
Clinical Cure96.8 (88.8 to 99.6)87.5 (47.3 to 99.7)
Clinical Failure0.0 (NA to NA)12.5 (NA to NA)
Indeterminate3.2 (NA to NA)0.0 (NA to NA)
SecondaryPercentage of Participant With Clinical Response at Day 180 in the mITT Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

Time frame:
Day 180
Reported as:
Number · percentage of participants
Percentage of Participant With Clinical Response at Day 180 in the mITT Population
percentage of participantsDalbavancinStandard of Care
Clinical Cure94.0 (85.4 to 98.3)87.5 (47.3 to 99.7)
Clinical Failure3.0 (NA to NA)0.0 (NA to NA)
Indeterminate3.0 (NA to NA)12.5 (NA to NA)
SecondaryPercentage of Participants With Clinical Response at Day 180 in the CE Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

Time frame:
Day 180
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Day 180 in the CE Population
percentage of participantsDalbavancinStandard of Care
Clinical Cure95.5 (87.3 to 99.1)87.5 (47.3 to 99.7)
Clinical Failure1.5 (NA to NA)0.0 (NA to NA)
Indeterminate3.0 (NA to NA)12.5 (NA to NA)
SecondaryPercentage of Participants With Clinical Response at Day 365 in the mITT Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

Time frame:
Day 365
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Day 365 in the mITT Population
percentage of participantsDalbavancinStandard of Care
Clinical Cure94.0 (85.4 to 98.3)87.5 (47.3 to 99.7)
Clinical Failure3.0 (NA to NA)0 (NA to NA)
Indeterminate3.0 (NA to NA)12.5 (NA to NA)
PrimaryPercentage of Participants With Clinical Response at Day 365 in the CE Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

Time frame:
Day 365
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Response at Day 365 in the CE Population
percentage of participantsDalbavancinStandard of Care
Clinical Cure95.5 (87.3 to 99.1)87.5 (47.3 to 99.7)
Clinical Failure1.5 (NA to NA)0 (NA to NA)
Indeterminate3.0 (NA to NA)12.5 (NA to NA)
SecondaryNumber of Participants With Clinical Cure by Baseline Pathogen at Day 42 in the CE Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

Time frame:
Day 42
Reported as:
Number · participants
Number of Participants With Clinical Cure by Baseline Pathogen at Day 42 in the CE Population
participantsDalbavancinStandard of Care
Staphylococcus aureus415
Staphylococcus epidermidis62
Staphylococcus haemolyticus3—
Staphylococcus pasteuri1—
Staphylococcus hominis1—
Staphylococcus simulans1—
Enterococcus faecalis71
Enterococcus faecium1—
Streptococcus agalactiae11
Streptococcus dysgalactiae1—
Streptococcus pyogenes1—
Corynebacterium striatum21
Aerococcus viridans1—
Globicatella species1—
Micrococcus luteus1—
Peptoniphilus harei2—
Anaerococcus prevotii1—
Finegoldia magna1—
Peptostrep. anaerobius1—
Escherichia coli3—
Klebsiella pneumoniae21
Pseudomonas aeruginosa20
Enterobacter cloacae complex2—
Morganella morganii2—
Proteus mirabilis11
Raoultella planticola10
Serratia marcescens—0
Escherichia hermannii1—
Pluralibacter gergoviae1—
Acinetobacter calcoaceticus1—
Bacteroides fragilis2—
Bacteroides thetaiotaomicron1—
Bacteroides vulgatus1—
Porphyromonas asaccharolytica2—
Prevotella melaninogenica2—
Prevotella disiens1—
Prevotella intermedia1—
Prevotella species1—
SecondaryNumber of Participants With Clinical Cure by Baseline Pathogen at Day 180 in the CE Population

Clinical response was either cure, failure or indeterminate. A cure was defined as recovery without need for additional antibiotic therapy. A failure was defined as the requirement of additional antibiotic therapy for no response or worsening after improvement, new purulence, amputation due to progression of infection (from initiation of study drug to outcome assessment visit), requiring \>6 weeks of antibiotic therapy for participants in the standard of care arm or death (for any reason). Indeterminate was defined as lost to follow-up or amputation due to vascular insufficiency (from initiation of study drug to outcome assessment visit).

Time frame:
Day 180
Reported as:
Number · participants
Number of Participants With Clinical Cure by Baseline Pathogen at Day 180 in the CE Population
participantsDalbavancinStandard of Care
Staphylococcus aureus395
Staphylococcus epidermidis62
Staphylococcus haemolyticus3—
Staphylococcus pasteuri1—
Staphylococcus hominis1—
Staphylococcus simulans1—
Enterococcus faecalis70
Enterococcus faecium1—
Streptococcus agalactiae11
Streptococcus dysgalactiae1—
Streptococcus pyogenes1—
Corynebacterium striatum21
Aerococcus viridans1—
Globicatella species1—
Micrococcus luteus1—
Peptoniphilus harei2—
Anaerococcus prevotii1—
Finegoldia magna1—
Peptostrep. anaerobius1—
Escherichia coli3—
Klebsiella pneumoniae21
Pseudomonas aeruginosa21
Enterobacter cloacae complex2—
Morganella morganii2—
Proteus mirabilis11
Raoultella planticola11
Serratia marcescens—1
Escherichia hermannii1—
Pluralibacter gergoviae1—
Acinetobacter calcoaceticus1—
Bacteroides fragilis2—
Bacteroides thetaiotaomicron1—
Bacteroides vulgatus1—
Porphyromonas asaccharolytica2—
Prevotella melaninogenica2—
Prevotella disiens1—
Prevotella intermedia1—
Prevotella species1—

Adverse events

Collected over From Baseline (Day 0) to Day 365. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dalbavancin1/70 (1.4%)2/70 (2.9%)0/70 (0%)
Standard of Care0/10 (0%)0/10 (0%)0/10 (0%)
Most frequent serious events
Most frequent serious events
EventDalbavancinStandard of Care
Cardiac failure acuteCardiac disorders1/700/10
Inflammation of woundInjury, poisoning and procedural complications1/700/10

Baseline characteristics

Safety population included all intent-to-treat (ITT) participants who received any amount of randomized medication.

Age, Continuous
Age, Continuous(years)DalbavancinStandard of CareTotal
Mean49.2 ± 13.354.4 ± 15.349.8 ± 13.6
Sex: Female, Male
Sex: Female, Male(Participants)DalbavancinStandard of CareTotal
Female11516
Male59564
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DalbavancinStandard of CareTotal
White701080
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DalbavancinStandard of CareTotal
Not Hispanic or Latino701080
08

Study locations

1 site
  • Allergan Investigative Site 001
    Cherkasy, 18009, Ukraine
09

References and documents

Publications

  • Rappo U, Puttagunta S, Shevchenko V, Shevchenko A, Jandourek A, Gonzalez PL, Suen A, Mas Casullo V, Melnick D, Miceli R, Kovacevic M, De Bock G, Dunne MW. Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety. Open Forum Infect Dis. 2018 Dec 10;6(1):ofy331. doi: 10.1093/ofid/ofy331. eCollection 2019 Jan. PubMed 30648126 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2016 to primary completion in Dec 2017, 20 months.

Results were first posted in Jan 2019, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2016
First posted
Feb 18, 2016
StartActual
Mar 15, 2016
Primary completionActual
Dec 12, 2017
CompletionActual
Dec 12, 2017
Results first posted
Jan 4, 2019
Last update
Jan 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02685033
Responsible party
Sponsor
First posted
Feb 18, 2016
Start date
Mar 15, 2016
Primary completion
Dec 12, 2017
Completion
Dec 12, 2017
Results posted
Jan 4, 2019
Last update
Jan 4, 2019

Study contacts

Urania Rappo, MD, MS, PharmD
study director · Allergan

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dalbavancin

Start the discussion